Frank Nestle

Frank Nestle is a Partner at Deerfield Management and CEO of 3DC, where he invests in therapeutics with a focus on immunology, oncology, neuroscience, rare diseases, and genomic medicine, including company creation and advancing programs from discovery to clinical proof of concept. He has invested from seed through post-IPO equity across healthcare (including biotechnology, pharmaceuticals, diagnostics, healthcare services, and medical technology) in companies such as Owkin, Reprieve Cardiovascular, Petfolk, CalciMedica, and Solid Biosciences. He serves on or has served on the boards of Kiadis Pharma (Chairman, 2021–2022), Owkin (Board Observer, 2022–2024), and Guy's and St. Thomas' Foundation Trust Hospital (Non-Executive Director, 2009–2016). Before Deerfield, he held roles including Global Head of Research and Chief Scientific Officer at Sanofi; Global Head of Immunology Therapeutic Research Area and Chief Scientific Officer North America at Sanofi; Senior Investigator Emeritus at the National Institute of Health Research; Professor and Director roles at King's College London; Director of Clinical Research Facilities at Guy's and St. Thomas' Hospital and King's College London; Consultant Dermatologist (Honorary) at Guy's and St. Thomas' Hospital; Faculty Member, Entrepreneurs in Clinical Academia at INSEAD/FOCIS; and Visiting Associate Professor at Rockefeller University. Frank was educated at The Julius Maximilians University of Würzburg and resides in New York.